China’s Drugmakers Shift Toward AI-Enabled Doctor Marketing

By Grace Kim

Frost & Sullivan estimates that Chinese enterprise spending on digital health marketing will grow at a 27.5% compound annual rate from 2027 to 2030, reaching RMB274.4 billion. The estimate covers the broader category and provides no separate figure for physician-facing AI applications.

Reuters reported on November 11, 2026, that pharmaceutical companies in China are exploring marketing through medical AI assistants and customized, disease-specific academic platforms as stricter anti-corruption enforcement complicates traditional visits to doctors and hospitals.

What changes under anti-graft enforcement?

Reuters reported that a multiyear campaign against healthcare bribery and corruption intensified in summer 2026. Authorities introduced stricter measures for pharmaceutical employees who provide product information to doctors and hospitals.

Medlive’s August 28, 2026, interim results describe sustained enforcement and medical-representative rules as raising compliance requirements. The company said drugmakers have reduced traditional promotional spending and increased the budget share for digital academic marketing built around traceable clinical evidence.

An Alibaba Health survey of hundreds of doctors found that 93% used AI tools, compared with about 70% a year earlier. The comparison indicates rapid adoption, but Alibaba Health’s survey measures AI tools broadly rather than usage of any one platform.

Null Hypothesis CEO Gu Fei said the shift moves away from hospitality and gift-giving toward tools that support clinical work and research. From a doctor’s perspective, he said, “this really gives me a new capability and helps me improve efficiency, rather than you giving me two bottles of Moutai.”

Medlive’s results point to one change: promotional budgets are moving toward digital tools that leave a traceable evidence trail.

Which AI marketing models are real?

Gu said major Chinese and foreign drugmakers have licensed Null Hypothesis’s KnowS product to build physician-facing academic platforms focused on particular diseases. He declined to name the companies.

Alibaba Health is considering placing promoted research and clinical evidence beside relevant AI-generated answers on Hydrion. The company has not begun drugmaker collaborations on Hydrion, although chief technology officer Wang Xiangzhi described interest from domestic and foreign companies as strong.

Yidu Tech has discussed search prominence and academic endorsements with drugmakers, but it is not yet offering those functions on Yidu Evidence.

Roche said it explores third-party medical AI tools for direct marketing to doctors and hospitals. Bayer said it monitors technology that could support compliant engagement with healthcare professionals.

Reuters’ November 11 assessment separates live licensing and customer growth from sponsored answers and preferred search, which remain proposals.

What tools reach doctors?

Alibaba Health’s Hydrion product page lists literature and guideline searches, drug-information lookup, AI question answering, PDF translation and summarization. The page also lists content collaborations with BMJ, JAMA and NEJM.

The listed Hydrion resources include 40 million papers, more than 30,000 guidelines and more than 60,000 drug instructions.

JD Health’s September 8, 2026, account of Zhiyi says the assistant launched in January 2026 and had served more than one million doctors while supporting over 20 million clinical decision-making interactions. Its evidence-location feature identifies the original text supporting a clinical point, allowing physicians to trace generated information back to the underlying evidence.

JD Health formed its PICA Health partnership in August 2026 and made Zhiyi free to registered primary-care doctors through PICA’s app. PICA Health says the platform limits AI-embedded content to disease education, clinical guidelines and care standards.

The policy excludes branded drug recommendations and product-oriented content, and PICA Health says that content undergoes academic review.

PICA Health’s policy leaves branded drug recommendations and product content outside Zhiyi, even as the assistant reaches registered primary-care doctors for free.

Why is revenue lagging activity?

Medlive’s first-half 2026 results show 217 healthcare customers for precision marketing and corporate solutions, up from 191 a year earlier. Marketed products rose from 445 to 509, while segment revenue increased 1.1% to RMB295.5 million.

Medlive attributed the gap between expanding activity and modest revenue growth to two pressures. Stricter regulation disrupted physicians’ participation in online and offline academic activities and delayed some projects, while smaller pharmaceutical marketing budgets constrained near-term investment in digital academic marketing.

Reuters said the market is already partly commercial: KnowS licensing and Medlive’s customer growth are operating business, while promoted evidence beside AI answers and preferred search placement remain proposals.

Reuters framed the unresolved issue: platforms must keep physician education and traceable clinical evidence distinct from brand-directed promotion if drugmakers want deeper access to doctors’ daily workflows.